Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 8—August 2020
Research

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France

Marie JaspardComments to Author , Nathalie Butel, Najoua El Helali, Dhiba Marigot-Outtandy, Helene Guillot, Gilles Peytavin, Nicolas Veziris, Bahram Bodaghi, Philippe Flandre, Gregoire Petitjean, Eric Caumes, and Valerie Pourcher
Author affiliations: Sorbonne Université, Paris, France (M. Jaspard, H. Guillot, N. Veziris, B. Bodaghi, E. Caumes, V. Pourcher); Assistance Publique–Hôpitaux de Paris, Hôpitaux Universitaires Pitié-Salpêtrière Charles Foix, Paris (M. Jaspard, H. Guillot, E. Caumes, V. Pourcher); Assistance Publique – Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris (N. Butel, B. Bodaghi); Groupe Hospitalier Paris Saint Joseph, Paris (N. El Helali, G. Petitjean); Bligny Medical Center, Briis sous Forges, France (D. Marigot-Outtandy); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Paris (G. Peytavin); Université Paris Diderot, Sorbonne Paris Cité, Paris (G. Peytavin); Assistance Publique–Hôpitaux de Paris, Hôpitaux Universitaires de l’Est Parisien, Paris (N. Veziris); Institut Pierre Louis Institute d’Épidémiologie et de Santé Publique, Paris (P. Flandre, E. Caumes, V. Pourcher)

Main Article

Table 3

Characteristics of 14 patients who experienced optic neuropathy after linezolid treatment for multidrug-resistant tuberculosis, Pitié-Salpêtrière Hospital, Paris, France, 2011–2016*

Patient age, y/sex, Fundus examination Visual color† Visual field Involvement Other Linezolid duration, mo Months from start of linezolid to onset of optic neuropathy Reversibility after linezolid withdrawal
37/M
Papillary edema
Tritanopia
BSE
B
None
3.4
0.0
No
42/M
WNL
Tritanopia
Aciform scotoma
B
None
13.5
1.4
No
20/M
WNL
Tritanopia
WNL
B
None
18.5
1.6
Yes
40/M
WNL
Tritanopia
BSE
B
Optic neuropathy confirmed by VEP
15.3
14.6
Yes
48/M
WNL
Tritan
BSE
B
None
5.7
9.3
No
43/M
WNL
Tritanopia
NA
U
None
11.6
17.9
Yes
40/M
WNL
Tritanopia
BSE
U
None
18
NA
Yes
39/M
WNL
Tritanopia
BSE
B
None
23.1
15.4
Yes
42/M
WNL
Tritanopia
BSE
B
None
19.4
5.2
Yes
40/M
WNL
Tritanopia
NA
B

4.4
1.0
No
34/M
Papillary edema
Tritanopia
BSE
B
Optic neuropathy confirmed by VEP
16.6
15.1
Yes
21/M
Papillary edema
Tritanopia
Scotoma
B
Optic neuropathy confirmed by VEP
7.1
8.2
Yes
23/F
Hyperemia of optical nerve
Tritanopia
BSE
B
None
NA
10.2
Yes
30/M Hyperemia of optical nerve Tritan BSE B None 19.1 16.2 Yes

*B, bilateral; BSE, blind spot enlargement; NA, not available; U, unilateral, VEP, visual evoked potential; WNL, within normal limits.
†Tritan, common blue–yellow color blindness.; tritarnopia, blue–yellow confusion typical in patients with optic neuropathies.

Main Article

Page created: June 12, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external